Zealand Pharma announced a collaboration with Generate Biomedicines on October 13 worth up to $1.2 billion, pairing the Danish drugmaker’s obesity and metabolic disease expertise with Generate’s AI-driven protein design platform to develop new treatments in a category that has become one of the pharmaceutical industry’s most lucrative battlegrounds.
The Deal Structure
Zealand will make an upfront payment of $30 million to Generate, with the agreement initially covering two experimental drug programs and an option to add a third, structured with milestone payments that could bring the total deal value to $1.2 billion if the programs progress successfully through development. The arrangement gives Zealand access to Generate’s generative AI models for designing novel protein-based therapeutics without having to build that capability internally.
Why Obesity Drugs Are the Focus
The obesity drug market has exploded in value following the commercial success of GLP-1 therapies from Novo Nordisk and Eli Lilly, creating intense competitive pressure for other pharmaceutical companies to develop differentiated treatments, whether through improved efficacy, fewer side effects, or more convenient dosing. Zealand, a smaller player relative to the market leaders, is betting that Generate’s AI protein design capabilities can help it discover candidates with meaningfully different mechanisms than the current generation of GLP-1 drugs.
How Generate’s Technology Works
Generate Biomedicines uses generative AI models, conceptually similar to the architectures behind large language models, to design novel protein structures with specific therapeutic properties, an approach the company argues can explore a much larger space of possible drug candidates than traditional structure-based design methods. The company has pursued similar partnerships across multiple disease areas as it builds out a portfolio of pharma collaborations to generate near-term revenue while its own pipeline matures.
Part of a Broader Wave of AI Pharma Deals
The Zealand-Generate deal is one of several major AI drug discovery partnerships announced in October alone, following AstraZeneca’s collaboration with Insitro and joining a growing list that includes Eli Lilly’s deals with Insilico and Profluent, Boehringer Ingelheim’s partnership with Owkin, and GSK’s deal with Relation Therapeutics. The clustering of announcements suggests pharmaceutical companies are racing to secure AI drug discovery partnerships before the best available technology platforms are locked up by competitors.
Skepticism About Near-Term Payoff
As with other AI drug discovery deals, the Zealand-Generate partnership will take years to produce clinical results, and the broader industry still awaits its first AI-substantially-designed drug to reach market approval, leaving the deal’s ultimate value dependent on scientific outcomes that remain unproven at this stage. Analysts note the obesity drug category’s enormous commercial upside makes even speculative AI-driven bets more justifiable than in smaller therapeutic areas.
What’s Next
Zealand and Generate are expected to begin preclinical work on the initial two drug programs in the near term, with any decision to exercise the option for a third program likely to depend on early results. Investors will watch for updates on program progress in Zealand’s upcoming quarterly reports as an early signal of whether the partnership is advancing on schedule.
Photo: Peggy_Marco / PIXABAY via Pixabay
